相关实验视频
Updated: Jul 26, 2026
10:43
Modeling Oral-Esophageal Squamous Cell Carcinoma in 3D Organoids
Published on: December 23, 2022
3.5K
综合的基因组和转录基因组分析揭示了食道状细胞癌的预后分层
Jian Gao1,2,3,4, Qiming Wang4, Fangqiu Fu1,2,3
1Department of Thoracic Surgery and State Key Laboratory of Genetics and Development of Complex Phenotypes, Fudan University Shanghai Cancer Center, Shanghai, China.
Signal transduction and targeted therapy
|July 16, 2025
概括
消化管状细胞癌 (ESCC) 的异质性使用多种omics进行了分析. 由S100A8+S100A9标记的上皮皮质角质化 (EpK) 途径预测了良好的预后,而其他亚型表明不良结果.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 分子生物学分子生物学
背景情况:
- 食道状细胞癌 (ESCC) 呈现出显著的异质性,使预后标志物识别和患者分层复杂化.
- 之前的多学科研究已经提供了洞察力,但临床管理仍然不一致.
研究的目的:
- 通过综合基因组和转录基因组分析来表征ESCC异质性.
- 确定新的预后标志物,并开发ESCC的患者分层系统.
主要方法:
- 来自ECTOP-2002研究的203名ESCC患者的基因组和转录组分析.
- 分析突变特征 (mucin家族,APOBEC) 和通路激活 (上皮皮质化/EpK).
- 验证S100A8+S100A9复合物作为EpK通路标记物,并开发FU-ESCC亚型系统.
主要成果:
- 粘真菌家族突变和APOBEC签名与ESCC的不良预后相关.
- 皮质角质化 (EpK) 途径的激活与良好的预后和减少化疗后复发有关.
- FU-ESCC亚型确定了三种不同的亚型:epK激活 (有利),癌症相关纤维细胞 (CAF) 丰富 (差),免疫沙漠 (差).
结论:
- S100A8+S100A9复合体是EpK通路的关键标志物,在ESCC中具有有利的预后.
- FU-ESCC亚型系统有效地根据分子和临床特征对患者进行分层.
- 这项研究为精准医学和ESCC管理中的向疗法提供了宝贵的见解.
相关概念视频
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...